Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bravo, well done Gman!
yesterday was profit taking, today is go time!
I saw that as well, it has been shorted by almost 50% of volume for the past 5 days.
Along with the golden cross :)
Possibly looking at a 100 million in volume today.
Nice churning going on right here.
Huge bid right now, wow wow wee wow!
Nice DD stervc, the "potential" for MINE is just starting.
MINE .0035s up!
.0034s almost gone!
Do the math on this, I own 5 milly @ .0025 and if I sell at .02?
Go MINE
A little dip before a run.
tic toc tic toc.
.0031 thinning out.
MINE
buys out numbering sells, so far today.
bids looking better
I'm on the bid someone feed me a few milly here.
Interesting here, like the share structure. Waiting on the side for now, before I drop a few G's into this.
Chart looks good, whats the current float here?
IDIX broke resistance.
From a technical standpoint, the 20dma and 30dma are close to crossing the 50dma plus the macd is heading to a positive position. Looking for a breakout, glta.
IDIX moving slow and steady, like a turtle.
IDIX moving slow and steady.
IDIX potential bottom play.
http://stockcharts.com/h-sc/ui?s=IDIX&p=D&b=5&g=0&id=p37623705924
Bought IDIX, based on the chart setup for a bounce.
Looks good for a bounce, any near term catalyst?
Sold RMTI at 4.94 from my 3.90 entry for almost a 27% gain. Now waiting for APPY, bought in at 1.31 a few weeks ago.
RMTI 20dma crossing 50dma with up coming events.
Bought in today with a few grand.
ECTE bottom play, looking for the bounce.
Echo Therapeutics Announces Closing of Public Offering of Common Stock
Print
Alert
Echo Therapeutics, Inc. (MM) (NASDAQ:ECTE)
Intraday Stock Chart
Today : Wednesday 6 February 2013
PHILADELPHIA, Feb. 6, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the closing of a previously announced underwritten public offering of 13,633,333 shares of its common stock and the full exercise of the over-allotment option to purchase 2,045,000 additional shares, offered at a price to the public of $0.75 per share. The gross proceeds to Echo from this offering are approximately $11.76 million, before deducting the underwriting discount and other estimated offering expenses payable by Echo.
(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )
Aegis Capital Corp. acted as the sole book-running manager for the offering.
Feltl and Company acted as co-manager for the offering.
The offering is being made pursuant to a shelf registration statement that Echo previously filed with the Securities and Exchange Commission (the "SEC") and which is effective. A final prospectus supplement and accompanying base prospectus has been filed with SEC and is available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system. Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care. Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements, including statements regarding Echo's proposed public offering. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks and uncertainties identified and described in more detail in Echo's filings with the Securities and Exchange Commission. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com
Rollercoaster ride today..When do they start voting?
If not Ampligen, then what other known treatment is available then, to help out the people with CFS/ME?
Indeed, thank you.
It would be nice if it did have the same pop.
TDEY looks like it is almost ready to run.
Setting up for a major reversal imo, slow sto curling up.
Nice to see a good close today.
Tic toc tic toc :)
Nice pick up!